Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology 2024-11-11 08:07
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase® 2024-07-08 21:00
Altos Biologics Files for Approval of Aflibercept Biosimilar 2024-07-02 08:00
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile 2023-09-05 20:00
Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration 2023-02-22 22:00
1